Home Healthcare IT Dyslexia Treatment and Diagnosis Market Size, Trends & Growth Report 2032

Dyslexia Treatment and Diagnosis Market

Dyslexia Treatment and Diagnosis Market Size, Share & Trends Analysis Report By Type (Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia, Others), By Drug Class (Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reputake Inhibitors, Others), By End-User (Psychiatric Institutions, Rehabilitation Centres, Home Care, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI3724DR
Study Period 2020-2032 CAGR 7.30%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD 28.43 billion
Forecast Year 2032 Forecast Year Market Size USD 53.63 billion
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global dyslexia treatment and diagnosis market size was valued at USD 28.43 billion in 2023. It is expected to reach USD 53.63 billion in 2032, growing at a CAGR of 7.30% over the forecast period (2024-32). Greater awareness and understanding of dyslexia among healthcare professionals, educators, and the general public drive demand for diagnosis and treatment options. Efforts to educate parents, teachers, and healthcare providers about dyslexia symptoms, early signs, and intervention strategies contribute to market growth.

Dyslexia is a condition when the patient struggles with writing, reading, and remembering unfamiliar or complicated words. Dyslexia is a neurological learning disorder found in various regions of people. Early management of dyslexia in children is possible with the use of specialized educational methods. In addition, various online programs and tools assist in improving the reading and learning problems of dyslexia disorder. The underlying brain variations that lead to dyslexia cannot yet be treated, but success can be increased with early discovery, examination, and selection of the most suitable therapy. Dyslexia is the most prevalent type of learning disability in children. Treatment often enables kids to develop their reading skills.

Market Dynamics

Global Dyslexia Treatment and Diagnosis Market Drivers

Increasing Prevalence of Dyslexia

A particular learning problem with neurological roots is dyslexia; according to studies worldwide, one in ten persons has dyslexia. Somewhere between 25-40% of children with dyslexia also have Attention Deficit Hyperactivity Disorder (ADHD), and conversely, approximately 25% of children with ADHD also have dyslexia. A whitepaper titled "The Economic Impact of Dyslexia on California," published by Boston Consulting Group (US) in July 2020, is estimated to cost California approximately USD 12 billion in 2020 and USD 1 trillion over the next 60 years.

A research article published online in 2021 in the Indian Journal of Psychiatric Nursing mentioned the incidence of dyslexia in Indian primary schoolchildren to be 2%– 18%, dysgraphia 14%, and dyscalculia 5.5%. India is thought to have approximately 90 million people with varying degrees of learning disabilities. Thus, a large population suffering from learning disabilities prone to developing dyslexia is increasing the number of patients with dyslexia. Additionally, an increasing number of learning programs focused on dyslexia are helping the growth of the global dyslexia treatment and diagnosis market.

Growing Number of Virtual Reality-Based Educational Software

Technology for simulating virtual environments has had implications in entertainment and learning environments. Virtual Reality-enabled (VR) classrooms are already showing a lot of promise. For instance, Lyfta, a Finnish educational technology company, uses VR headsets to create immersive worlds for students. VR could help students who have trouble with reading and pronouncing words correctly. With VR technology, dyslexic students may have layouts, text sizes and styles, and background colors tailored to their needs. Noteworthy head-mounted displays available in the market include Google Cardboard, Samsung Gear VR, and Oculus Rift. The reduction in the price of VR headsets is expected to increase the adoption of VR-based education apps.

The other objectives included using technology, specifically virtual reality (VR), to improve students' access, participation, and educational achievement with this learning difficulty. Studies found that VR-based learning provided with motivating environment for students with dyslexia. A growing number of software launched recently using VR to train people with dyslexia is expected to increase the overall market size during the forecast period.

Global Dyslexia Treatment and Diagnosis Market Restraint

Lack of Awareness about Dyslexia, Symptoms, and Diagnosis

Developmental dyslexia is one of the most typical neurobehavioral disorders affecting children. The global dyslexia treatment market might face challenges due to the lack of awareness among people about dyslexia and its symptoms. Another major restraint can be not having an early diagnosis of dyslexia. In addition, dyslexic students could require thorough training, testing accommodations, extra time for tests, homework, and taking notes in class. People with dyslexia can use some strategies, such as listening to audiobooks instead of reading, typing instead of writing, and using applications that can make learning engaging by turning decoding into a game. Therefore, lack of awareness and underdiagnosis related to dyslexia are expected to restrain the growth of the dyslexia treatment and diagnosis market.

Global Dyslexia Treatment and Diagnosis Market Opportunities

Rising Collaborations with Schools, Colleges, and Non-Profit Organizations

Many schools are focused on catering education for kids with learning difficulties. Similarly, non-profit organizations fund educational and financial resources for people with special needs. For instance, The Baily Thomas Charitable Fund provides funding to registered charities working with children or adults with severe learning difficulties and Autism. Likewise, "Follow your Dreams" helps young people with learning difficulties reach their full potential.

In contrast, Forbes Charitable Foundation supports small and medium-sized organizations with capital expenditure and some revenue expenditure in the form of grants. The developer of apps can collaborate with the government, curriculum designers, schools, and institutes of higher education to provide services and generate revenue. Similarly, app developers can attract investment and seed funding from charitable trusts to scale their operations, creating opportunities for market growth.

Regional Analysis

Based on region, the global dyslexia treatment and diagnosis market is divided into North America, Europe, Asia-Pacific, and the Rest of the World.

North America Dominates the Global Market

North America is the most significant contributor to the global dyslexia treatment and diagnosis market and is anticipated to grow at a CAGR of 6.15% during the forecast period. The market in the region is driven by a well-developed healthcare infrastructure, supportive governmental laws, substantial regional firm headquarters, like Jubilant Cadista (US) and Speechify (US), and a high prevalence of dyslexia. In addition, a learning-based problem, most frequently dyslexia, affects one in five pupils, or 15% to 20% of the US population, according to the Dyslexia Center of Utah. Additionally, the area is home to several non-profit organizations having a presence worldwide. These groups help sufferers and their families and raise public awareness of dyslexia. Several notable schools in the area cater to dyslexic students. There are over 100 private schools for people with dyslexia in the US and around six in Canada. The education ministries are also implementing policies driving growth for the market.

Europe is estimated to grow at a CAGR of 7.02% over the forecast period. Similar to North America, dyslexia is widespread in Europe. According to a December 2019 survey from The Institute of Entrepreneurship Development (iED), 15% of people in Europe have dyslexia. Furthermore, a significant portion of the 15% of people with dyslexia also has other co-morbid conditions. In addition to dyslexia, 20 to 40 percent of those with dyslexia also have dyscalculia, and 10 to 20 percent have anxiety issues. In the UK alone, about 6 million people are living. As a result, the region's need for high-quality medical care and diagnostic tools is excellent. Moreover, key players headquartered in the region are innovating and driving growth in the regional market. For instance, GlaxoSmithKline plc (UK) has a project named IT Accessibility Project that focuses on providing IT solutions to users and customers with disabilities, including dyslexia. The company also announced in June 2021 that it would drastically expand its specialty medicines portfolio over the next decade.

Asia-Pacific is the fastest-growing regional dyslexia treatment and diagnosis market, as it is developing rapidly and has witnessed the emergence of many players. There is a presence of several market players in the region who are driving growth for the market, such as Cian Healthcare Pvt Ltd. (India), Wallace Pharmaceuticals Ltd. (India), and RPG Life Sciences Ltd (India). There is also a high prevalence of dyslexia, driving the market growth. According to the Department of Biotechnology, in 2019, around 35 million children in India were suspected of people with dyslexia.

Additionally, counties in the Asia-Pacific regions have developed their dyslexia assessment tests to correctly identify the dyslexic population within the country and provide appropriate care. For instance, the National Brain Research Centre, India, developed the Dyslexia Assessment for the Languages of India (DALI) assessment test for children from classes 1-5. Similarly, Japan and Indonesia have also developed their dyslexia test battery for children. However, there is a high stigma regarding mental health disorders in the region which restricts people from getting diagnosed.

The rest of the world comprises the Middle East and Africa and Latin America. The rest of the world region showed restricted growth owing to a need for mental health awareness and facilities. In Africa, one in ten people is suspected of having dyslexia. Organizations such as Dyslexia International are running initiatives to train teachers to handle students with dyslexia and facilities like e-learning and campus for dyslexic children in Africa. The region's market growth is majorly due to the presence of developed countries in the Middle East, especially the Gulf countries.

Furthermore, countries like the United Arab Emirates have specialized schools and centers specifically for people with dyslexia in the Middle East. Taleem Training and Skill Development Center and Lexicon Reading Center are examples of the same. Globally accepted dyslexic tests are also being translated into Arabic languages to implement them in these countries. For instance, in Jordan in 2018, the Woodcock-Johnson IV assessment test was translated into Arabic. Such initiatives are driving growth for the regional market.

Report Scope

Report Metric Details
By Type
  1. Phonological Dyslexia
  2. Surface Dyslexia
  3. Double Deficit Dyslexia
  4. Others
By Drug Class
  1. Antihistamines
  2. Central Nervous Stimulant
  3. Selective Norepinephrine Reputake Inhibitors
  4. Others
By End-User
  1. Psychiatric Institutions
  2. Rehabilitation Centres
  3. Home Care 
  4. Others
Company Profiles Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Novartis AG Jubilant Pharma Limited GSK plc Eli Lilly and Company Otsuka Holdings Co., Ltd. Apotex Corporation Purdue Pharma Rhodes Pharmaceuticals L.P. Cian Healthcare Pvt. Ltd. Wallace Pharmaceuticals Ltd. The Himmel Group Astrazeneca Sun Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited Lupin
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global dyslexia treatment and diagnosis market is segmented by type, treatment and diagnosis, and end-user.

Based on type the market is segmented into phonological dyslexia, surface dyslexia, double deficit dyslexia, and others.

Phonological dyslexia segment is dominating in the market. This dominance is due to two key factors. First, phonological dyslexia are the most common type, affecting about 70% of dyslexia. This type of people has difficulties connecting letters to sounds and vice versa. Second, there are well-established interventions designed specifically for phonological dyslexia, such as phonological awareness training, that are effective in improving reading skills. Although there are other types of dyslexia, such as superficial and dual deficiency dyslexia, they are less common and treatments are still being developed. The Other category includes these less common variants.

Based on drug class the market is segmented into antihistamines, central nervous stimulant, selective norepinephrine reputake inhibitors, and others.

Unlike other conditions, medication is not the main treatment for dyslexia. The focus is on educational and therapeutic interventions. However, there are some medications on the market that are used to treat co-morbidities that are sometimes associated with dyslexia. There is no single dominant drug class here, as the choice depends on the specific problem. For example, in case of allergies, antihistamines can be prescribed, which prevent concentration during treatment. Central nervous system stimulants such as methylphenidate may be used if someone with dyslexia also has ADHD to improve concentration. Selective norepinephrine reuptake inhibitors (SNRIs) may be used to treat co-occurring anxiety or depression. The others category includes medications for less common comorbidities. In general, medications play a supportive role and therapeutic interventions remain at the heart of dyslexia treatment.

Based on end-user, the global market is segmented into specialty centers, home care, hospitals and clinics, and others.

The specialty center segment owns the highest market share and is expected to grow at a CAGR of 6.63% over the forecast period. Specialty centers are specialized settings for the treatment of mental health disorders. Specialty centers have gained demand in cases of dyslexia, as it is observed that children who have dyslexia also suffer from some other psychiatric disorder. According to a report published by Assiut University, Egypt, in July 2020, of children diagnosed with dyslexia, over 60% suffer from at least another psychiatric disorder. Therefore, specialty centers become essential to provide treatment and care for such co-morbid cases of dyslexia.

The home care segment is estimated to grow at a significant CAGR during the forecast period due to the increasing demand for dyslexia treatment methods at home. In-home settings, the child experiences the safest environment, which is ideal for learning. Moreover, ample facilities are available to help improve reading capabilities at home, such as apps, e-readers, virtual consulting sessions, and more.

Market Size By Type

Market Size By Type
  • Phonological Dyslexia
  • Surface Dyslexia
  • Double Deficit Dyslexia
  • Others
  • Recent Developments

    • January 2024 - A novel therapeutic strategy is being facilitated by Dysolve, the first artificial intelligence-powered platform for resolving dyslexia and related learning difficulties. Dyslexia is a neurological learning impairment that causes difficulties with reading, writing, and spelling for both adults and children. One in five persons suffer from the illness, which accounts for 80% to 90% of those with learning difficulties.
    • May 2024 - According to Senator England, the new bill will provide Mississippi's public schools with "a Swiss Army knife of a teacher." An interest group is attempting to persuade Governor Tate Reeves (R) to veto a law that seeks to make dyslexia therapy available to more pupils. The bill's sponsor is concerned about this. SB 2681, a bill presented by state senator Jeremy England (R) this session, would permit teachers who are certified in another state to offer dyslexia rehabilitation services to pupils in Mississippi's public schools.

    Key Players

    Dyslexia Treatment and Diagnosis Market Share of Key Players

    Dyslexia Treatment and Diagnosis Market Share of Key Players
    Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Novartis AG Jubilant Pharma Limited GSK plc Eli Lilly and Company Otsuka Holdings Co., Ltd. Apotex Corporation Purdue Pharma Rhodes Pharmaceuticals L.P. Cian Healthcare Pvt. Ltd. Wallace Pharmaceuticals Ltd. The Himmel Group Astrazeneca Sun Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited Lupin Others

    Frequently Asked Questions (FAQs)

    What is the market size of dyslexia treatment and diagnosis in 2023?
    The global dyslexia treatment and diagnosis market size was valued at USD 28.43 billion in 2023
    Key verticals adopting dyslexia treatment and diagnosis market include: -Pfizer Inc., Novartis AG, Eli Lilly & Company, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd, Speechify Inc., Jubilant Pharma Limited, Lingit AS (Lingit), Soli, Lyfta, RPG Lifesciences, HOPALAI D.O.O.
    Rising Collaborations with Schools, Colleges, and Non-Profit Organizations is one of the key trends in market.
    The global dyslexia treatment and diagnosis market growing at a CAGR of 7.3% from (2023–2032).

    We are featured on :